Infectious Diseases News and Research

RSS

Findings cast doubt on sepsis drug withdrawal

A meta-analysis of clinical trial and real-world data suggests that drotrecogin alfa may in fact reduce mortality in patients with severe sepsis.

24 Jul 2012

Novel combination drug regimen could be more effective than existing treatments for TB

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients' TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet.

24 Jul 2012

First Edition: July 24, 2012

Today's headlines include news from the campaign season as well as reports from the international AIDS conference currently taking place in Washington, D.C.

24 Jul 2012

TB combination drug trials progress

A novel approach to discover the first new tuberculosis (TB) combination drug regimen cleared a major hurdle when Phase II clinical trial results found it could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments, according to a study published today in the Lancet. These results add to a growing body of evidence that the new regimen could reduce treatment by more than a year for some patients.

24 Jul 2012

Study shows disturbing rates of new HIV infections among U.S. black MSM

Study results released today by the HIV Prevention Trials Network (HPTN) show disturbing rates of new HIV infections occurring among black gay and bisexual men in the U.S. (also known as men who have sex with men, or MSM), particularly young black MSM.

24 Jul 2012

PTC Therapeutics completes $30M financing

PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing investors.

23 Jul 2012

Placenta underlies reduced fetal movement

Poor perinatal outcome after the maternal perception of reduced fetal movement is linked to factors associated with placental dysfunction, say experts.

23 Jul 2012

AF deaths more likely on the weekend

In-hospital mortality rates for patients who have atrial fibrillation are significantly higher on the weekend than on weekdays, show US study results.

23 Jul 2012

First Edition: July 23, 2012

In this Kaiser Health News video, Greg Millett, a senior policy advisor in the Office of National AIDS Policy, tells Joanne Silberner that the president's National HIV/AIDS Strategy has improved coordination among federal agencies and that the 2010 health law will improve access to care for those living with HIV/AIDS.

23 Jul 2012

Study: Fewer Americans control their HIV infections

Tens of thousands of Americans taking potent antiretroviral therapies, or ART, to keep their HIV disease in check may not have as much control over the viral infection as previous estimates have suggested, according to results of a study by AIDS experts at Johns Hopkins and the University of Pennsylvania.

23 Jul 2012

Implementing multifaceted global effort may help end global HIV/AIDS pandemic

Ending the global HIV/AIDS pandemic may be possible by implementing a multifaceted global effort that expands testing, treatment, and prevention programs, as well as meets the scientific challenges of developing an HIV vaccine and possibly a cure, according to a Viewpoint in the July 25 issue of JAMA, a theme issue on HIV/AIDS.

23 Jul 2012

HIV-positive women may use new methods to help reduce frequency of cervical cancer screening

Compared to the general population, HIV-positive women have a high risk of cervical cancer and thus are advised to undergo more frequent screening tests. This creates a burden for HIV-positive patients and the health care system, leading to frequent biopsies, which often do not reveal clinically relevant disease.

23 Jul 2012

Bayer, Onyx and Astellas announce results from Tarceva plus Nexavar Phase 3 trial on HCC

Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals, Inc., and Astellas Pharma Inc. today announced that a Phase 3 trial evaluating the efficacy and safety of the addition of Tarceva (erlotinib) tablets to Nexavar (sorafenib) tablets did not improve overall survival for patients with unresectable hepatocellular carcinoma (HCC) vs. Nexavar alone.

23 Jul 2012

Study addresses African patients’ attitudes toward HIV antiretroviral therapy

An ongoing clinical study in rural Uganda, begun in 2011, suggests that many people infected with HIV/AIDS would take antiretroviral drugs if they were available to them—even before they developed symptoms from the disease.

23 Jul 2012

As AIDS conference opens, health panel urges treatment of all HIV infections

An international health panel has recommended for the first time that all HIV patients be treated with antiretroviral drugs, even when the virus's impact on their immune system is shown to be small. The nonprofit International Antiviral Society-USA cited new evidence that untreated infection with the human immunodeficiency virus that causes AIDS can also lead to a range of other conditions, including cardiovascular disease and kidney disease.

23 Jul 2012

Researchers identify high ARV drug exposure in hair samples of HIV uninfected infants

Researchers from the University of California, San Francisco (UCSF) and Makerere University in Uganda have used hair and blood samples from three-month old infants born to HIV-positive mothers to measure the uninfected babies' exposure—both in the womb and from breast-feeding—to antiretroviral medications their mothers were taking. The results, they said, are surprising.

23 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

New CHAIT initiative on development of novel immunological therapeutic interventions

The CHAIT initiative is a public-private partnership focusing on the development of novel immunological therapeutic interventions to achieve a 'functional HIV cure' with the ultimate goal of HIV eradication.

21 Jul 2012

Study explores role of L. reuteri against foodborne infection

While many bacteria exist as aggressive pathogens, causing diseases ranging from tuberculosis and cholera, to plague, diphtheria and toxic shock syndrome, others play a less malevolent role and some are critical for human health.

21 Jul 2012

Study opens way for new approaches to slow development of AIDS in HIV-1-infected patients

A new study from Lund University in Sweden has opened the way for new approaches to slowing the development of AIDS in HIV-1-infected patients. It is hoped that this could lead to better treatment methods and preventive measures to combat HIV and AIDS.

20 Jul 2012